Emergent BioSolutions (NYSE:EBS) will invest
$75M in its Canton, Massachusetts facility, focused on the development
and manufacturing of drug substance for live viral vaccines and plans to
expand into viral vector and gene therapy.
The investment will include a state-of-the-art, multi-suite operation up to 1000L scale.
The company plans to provide full
molecule-to-market contract development and manufacturing services by
offering development services out of its Gaithersburg location, drug
substance manufacturing out of Canton, and drug product manufacturing at
its Rockville, Md. location.
https://seekingalpha.com/news/3584054-emergent-bio-to-invest-75m-in-canton-site
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.